The discovery of activating mutations of the epidermal growth factor receptor (EGFR) in patients with lung adenocarcinoma led to the development of a new family of biological agents, called tyrosine kinase inhibitors (TKIs), that have revolutionized the clinical management of LC patients. This evidence concerns the gene EGFR and lung adenocarcinoma.